Pieris Pharmaceuticals Inc
NASDAQ:PIRS
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
100.1m USD |
-40%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-391%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
330.7B USD |
3%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.7B USD |
7%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
136B USD |
11%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD |
-4%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-67%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
118.8B AUD |
7%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
52.8B USD |
13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-21%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.9B USD |
-7%
|
Pieris Pharmaceuticals Inc
Glance View
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Pieris Pharmaceuticals Inc's most recent financial statements, the company has ROA of -39.9%.
You don't have any saved screeners yet